| 产品详情 |
| Edit |   |
|---|
| Product Name | LDN-212854 |
|---|
| Description | Purity >98%. Activation of bone morphogenetic protein (BMP) type I receptors, also known as activin receptor-like kinases (ALK1-7), leads to the assembly of SMAD complexes, which translocate to the nucleus to induce transcriptional activation important for normal development and tissue repair. LDN-212854 inhibits ALK2 (IC50 = 1.3 nM) in preference to other BMP type I receptors, ALK1 (IC50 = 2.4 nM) and ALK3 (IC50 = 85.8 nM) and with over 1,500-fold selectivity against the closely related activin and TGF-Beta type I receptors (i.e., ALK4 and ALK5). It has been shown to inhibit BMP6-induced osteogenic differentiation, which functions predominantly via ALK2, with an IC50 value of 10 nM. LDN-212854 also demonstrates off-target activity against RIPK2, ABL1, and PDGFRBeta kinases with IC50 values less than 100 nM. |
|---|
| Size | n/a |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | 5-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline |
|---|
| Gene, Accession, CAS # | CAS: 1432597-26-6 |
|---|
| Catalog # | LS-H8436 |
|---|
| Price | |
|---|
| Order / More Info | LDN-212854 from LIFESPAN BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|